Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase 1 Study to Evaluate the PK, Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, Cabotegravir (CAB; GSK1265744) in HIV Uninfected Chinese Men

NCT03422172 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT03422172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03422172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase 1 Study to Evaluate the PK, Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, Cabotegravir (CAB; GSK1265744) in HIV Uninfected Chinese Men
Lead sponsor
ViiV Healthcare
Phase
Phase 1
Overall status
Completed
Start date
April 10, 2018
Completion date
April 20, 2020
Enrollment
48 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections